Carboplatin (carboplatin)

Dosage of carboplatin must be based on the clinical, renal, and hematologic response and tolerance of the patient in order to obtain optimum therapeutic response with minimum adverse effects. While initial carboplatin dosage can be based on body surface area, dosage may be more accurately calculated using formula dosing methods based on the patient's renal function. Because renal function often is reduced in geriatric patients, the manufacturer recommends that dosing formulas incorporating estimates of glomerular filtration rate be used in geriatric patients to help minimize the risk of toxicity. The manufacturer recommends that carboplatin generally be given no more frequently than once every 4 weeks at usual dosage. A repeat course of carboplatin should not be administered until the patient's hematologic functions are within acceptable limits, and precautions must always be taken to treat a hypersensitivity reaction if it occurs. When carboplatin is used as a component of a multiple-drug regimen, clinicians should consult published protocols for the dosage of each chemotherapeutic agent and the method and sequence of administration.

Because carboplatin is an antineoplastic agent of moderate emetic risk, antiemetic therapy is recommended.

Dosage of carboplatin should be reduced in patients with impaired renal function. Because patients with creatinine clearances less than 60 mL/minute are at increased risk of myelosuppression during carboplatin therapy, dosage in such patients should be adjusted according to the degree of renal impairment. When carboplatin is used alone in the treatment of recurrent ovarian carcinoma in patients with renal impairment, the manufacturer recommends that those with creatinine clearances of 41-59 mL/minute receive an initial dose of 250 mg/m2 and those with creatinine clearances of 16-40 mL/minute receive an initial dose of 200 mg/m2. The incidence of severe leukopenia, neutropenia, or thrombocytopenia in these patients at these dosages is about 25%. Subsequent carboplatin dosage should be adjusted according to the patient's hematologic tolerance to the previous dose. Although carboplatin has been used in a limited number of patients with creatinine clearances less than 15 mL/minute, the manufacturer states that experience in these patients is too limited to make dosage recommendations.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Carboplatin can cause fetal toxicity when administered to pregnant women, but potential benefits from use of the drug may be acceptable in certain conditions despite possible risks to the fetus. Carboplatin has been shown to be embryotoxic and teratogenic in rats. Reproductive studies in rats receiving carboplatin during organogenesis revealed evidence of embryotoxicity and teratogenicity. There are no adequate or controlled studies to date using carboplatin in pregnant women. Carboplatin should be used during pregnancy only in life-threatening situations or for disease for which safer drugs cannot be used or are ineffective. If the drug is administered during pregnancy or if the patient becomes pregnant while receiving carboplatin, the patient should be informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during carboplatin therapy.

It is not known whether carboplatin or its platinum-containing products are distributed into human milk. Because of the potential for serious adverse reactions to carboplatin in nursing infants if the drug were distributed into milk, nursing should be discontinued during carboplatin therapy.

No enhanced messaging available.